Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Glioma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans Syndrome 1Brain Neoplasms 1

Interventions

fludarabine 7Tacrolimus 6Cyclophosphamide 6Whole-Body Irradiation 5Mycophenolic Acid 5Busulfan 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Imatinib Mesylate 4Cytarabine 4Sirolimus 3Melphalan 3thymoglobulin 2asciminib 2Thiotepa 2Patient Reported Outcome Measures 2Mesna 2Bone Marrow Transplantation 2Antilymphocyte Serum 2venetoclax 1ponatinib 1pegfilgrastim 1nilotinib 1nicotinamide-beta-riboside 1methanesulfonic acid 1lonafarnib 1lestaurtinib 1glasdegib 1flumatinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid × lonafarnib × Clear all
NCT00038597 2018-10-30

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡